West Pharmaceutical Services, Inc.
WST
$355.64
$1.530.43%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.93B | 2.95B | 2.93B | 2.87B | 2.88B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.93B | 2.95B | 2.93B | 2.87B | 2.88B |
| Cost of Revenue | 1.84B | 1.82B | 1.81B | 1.77B | 1.76B |
| Gross Profit | 1.09B | 1.13B | 1.11B | 1.09B | 1.12B |
| SG&A Expenses | 354.80M | 354.10M | 299.00M | 325.60M | 318.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -3.10M | -3.00M | -3.30M | -1.70M | -2.40M |
| Total Operating Expenses | 2.26B | 2.24B | 2.17B | 2.16B | 2.14B |
| Operating Income | 668.30M | 710.50M | 751.60M | 705.90M | 745.70M |
| Income Before Tax | 683.80M | 715.70M | 676.10M | 626.40M | 669.20M |
| Income Tax Expenses | 115.10M | 122.30M | 116.70M | 107.70M | 117.10M |
| Earnings from Continuing Operations | 568.70 | 593.40 | 559.40 | 518.70 | 552.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 568.70M | 593.40M | 559.40M | 518.70M | 552.10M |
| EBIT | 668.30M | 710.50M | 751.60M | 705.90M | 745.70M |
| EBITDA | 809.60M | 847.80M | 884.10M | 832.50M | 868.30M |
| EPS Basic | 7.68 | 7.99 | 7.52 | 6.97 | 7.42 |
| Normalized Basic EPS | 5.87 | 6.21 | 6.54 | 6.14 | 6.46 |
| EPS Diluted | 7.57 | 7.87 | 7.42 | 6.87 | 7.29 |
| Normalized Diluted EPS | 5.79 | 6.12 | 6.44 | 6.04 | 6.35 |
| Average Basic Shares Outstanding | 296.20M | 297.20M | 297.50M | 297.60M | 297.70M |
| Average Diluted Shares Outstanding | 300.00M | 301.40M | 302.00M | 302.40M | 302.80M |
| Dividend Per Share | 0.78 | 0.77 | 0.76 | 0.75 | 0.74 |
| Payout Ratio | 10.13% | 9.61% | 10.06% | 10.76% | 9.93% |
